The uptake of 75Se Selenomethionine by the pancreas has been evaluated in 102 patients and compared with the secretin-pancreozymin test of pancreatic function. In groups of patients with chronic pancreatitis and cancer of the pancreas abnormal scans closely parallel the diminished exocrine secretion, especially bicarbonate output, following a submaximal dose of secretin. Thirty per cent of the group with no pancreatic abnormality have abnormal scans, though the secretinpancreozymin test is normal. Though a normal scan excludes the presence of chronic pancreatitis and cancer of the pancreas with a probability greater than 90%, an abnormal scan is found so frequently in normal subjects that it does not provide a reliable index of impaired pancreatic function.
In the decade since Blau and Bender (1962) introduced ThSe Selenomethionine to scan the pancreas, numerous reports have confirmed its use in delineating the structure and position of the pancreas (Sodee, 1966; Centi Colella and Pigorini, 1967; Melmed, Agnew, and Bouchier, 1968) . The evidence that the scan also reflects pancreatic function rests on three studies. The first was confined to 19 diabetics (Lahdevirta, 1967) ; the second showed good general agreement between pancreatic function assessed by a secretin-pancreozymin test and 76Se Selenomethionine scans in 20 patients, though no details of the functional test were provided (Brown, Sircus, Smith, Donaldson, Dymock, Falconer, and Small, 1968) ; and the third compared duodenal tryptic activity following a Lundh-Borgstrom meal with 7"Se Selenomethionine scans of the pancreas in 54 subjects (McCarthy and Brown, 1969) . In the present study we have assessed 75Se Selenomethionine scanning as a test of pancreatic function by comparing it with the results of the secretin-pancreozymin test, considered to be the most useful test of pancreatic function currently available in clinical practice.
Methods
One hundred and thirty-six consecutive patients
Received for publication 21 February 1973. who attended between 1967 and 1971 for the investigation of suspected pancreatic disease were included in the study. All patients were examined clinically and a gastroenterological investigation was undertaken to establish the diagnosis. Laparotomy findings interpreted by the same surgical team were available in 57 patients. The secretin-pancreozymin test (Burton, Evans, Harper, Howat, Oleesky, Scott, and Varley, 1960) and the 75Se Selenomethionine scan of the pancreas (Charlesworth, Testa, Pullan, and Torrance, 1970) were usually performed within a week of each other. In each case liver scanning using 99m Technetium colloid was carried out before the pancreatic scan. Thirty-four patients were subsequently omitted from the study for the reasons indicated in The scan of an elderly patient in whom the exocrine secretion was markedly reduced due to primary atrophy of the pancreas showed no uptake of 75Se Selenomethionine. A patient with partial agenesis of the head of the pancreas had a focal defect in the head of the gland on the scan, and an abnormal secretin-pancreozymin test.
Abnormal scans were recorded in 88 % of this group of 34 patients with chronic pancreatic disease (table VIII) which compares with an 88 % incidence of abnormal secretin-pancreozymin tests.
AFTER ACUTE PANCREATITIS
Of the 12 patients in this group, three who were scanned less than one month after the acute attack had diffuse abnormalities. In the nine patients scanned more than a month after the acute episode the scan was normal in six, and abnormal in three. One patient with a pseudocyst had a focal defect of the scan, in the other two uptake of 75Se Selenomethionine was diffusely reduced. The secretinpancleozymin test done more than three months after % 1600' 'c1200. Patients with chronic pancreatic disease Abnormal scans were recorded in 30 of the 34 patients (88 %) with chronic pancreatic disease. The volume of pancreatic juice was significantly reduced in 16 of these 30 patients (53 %), the output of bicarbonate after secretion was low in 27 patients (90%), and amylase output after pancreozymin was reduced in 17 (57%) (figs 2, 3, and 4).
Discussion
A frequent criticism of pancreatic scanning is the lack of objectivity in reporting and the consequent variability of scan reports depending on the experience of the observer. In this study three or more (table II) there was an increased incidence of unanimous reports (from 51 to 72) when the clinical details were made available to the observers.
In the 'control' group the incidence of abnormal scans was 30%. It should be appreciated that these patients in this control group were selected in that they all presented with abdominal symptoms to a clinical department. While such a population serves as a normal sample after pancreatic disease has been excluded, it may be that a few of these patients have had undetected pancreatic disease which may account for the abnormal scans. However, this is unlikely to be a major error since the proportion of abnormal scans was 26 % in the subgroup of 23 patients in whom the pancreas was adjudged normal at laparotomy. In addition, all but two of the 17 patients with abnormal scans in this control group had normal exocrine function assessed by the secretin-pancreozymin test. McCarthy, Brown, Melmed, Agnew, and Bouchier (1972) list 32 conditions with a high incidence of abnormal scans in which the appearance does not reliably reflect pancreatic morphology or function. These cover many common clinical conditions including diabetes mellitus and peptic ulcer. In the present study four of the 17 patients with abnormal scans (25%) were diabetic, an association recognized by Lahdevirta (1967) , and six of the seven patients with the clinical diagnosis of the spastic colon syndrome and one third of the patients with biliary disease had abnormal scans (table III) . The reason why patients with a normal pancreas may have abnormal scans has not yet been explained in physiological terms. Pancreatic scanning is of little diagnostic value during and immediately after an attack of acute pancreatitis but tends to reflect the return of pancreatic function to normal following the acute episode. Thus the appearance of scans vary with the timing of the scan in relation to the acute attack and no reliance should be placed on an abnormal scan within three to four weeks of an acute attack. We have followed the return of an abnormal scan to normal after acute pancreatitis in five of these cases. The scan may remain abnormal so long as a pseudocyst remains untreated.
The overall incidence ofscans interpreted as normal in the group of 34 patients with chronic pancreatic insufficiency was 9%. While the incidence of abnormal scans in chronic pancreatitis and cancer of the pancreas was 95% and 79% respectively, the scan fails to differentiate between the two conditions. Abnormal scans roughly paralleled diminished exocrine secretion in this group of patients. Since 75Se Selenomethionine uptake and enzyme secretion depend on acinar cell mass and function, a particularly good relationship was expected between abnormal scans and diminished levels of enzyme after pancreozymin. The amylase output was diminished in 57 % of patients with chronic pancreatitis and cancer of the pancreas with abnormal scans. In view of recent references which suggest that the amylase output in the normal population has a skew deviation (Sarles, Pastor, Pauli, and Barthelemy, 1963; Sun, 1963; Goldberg and Wormsley, 1970) , we speculated that the lower limit of the normal range of Burton et al (1960a) , which assumed that a Gaussian distribution might be too low and in part account for the relatively poor correlation obtained. We therefore computed the lower limit of the normal range for amylase in a group of 97 normal subjects using the non-parametric percentile estimate (Reed, Henry, and Mason, 1971 ). Using the PE lower limit the association between abnormal scans and decreased enzyme output in chronic pancreatic disease rose to 60 % for amylase and 66 % for trypsin. Corresponding values for volume and bicarbonate became 57 and 80% re3pvctively. The interrelation between abnormal scans and decreased output of bicarbonate was greater than the interrelation between abnormal scans and diminished amylase or trypsin output, a difference which may reflect in part the relatively crude methods available to estimate enzyme activity.
The incorporation of 75Se Selenomethionine into the acinar cells of the pancreas in the fed state may not correspond exactly to the output of enzyme excreted in the 30 minutes following pancreozymin in the secretin-pancreozymin test which is performed after a 12-hour fast, though Youngs, Agnew, Levin, and Bouchier (1971) found a reasonable correlation between radioactivity in the duodenal aspirate 90 to 120 minutes after 75Se Selenomethionine and the mean concentration of tryptic activity in 30-minute samples over 120 minutes following a LundhBorgstrom meal. In their recent review of pancreatic scanning Bachrach, Birsner, Izenstark, and Smith (1972) have suggested that manipulation of the diet and the injection of the intestinal secretory hormones secretin and pancreozymin may possibly alter the optimal time for scanning but this still remains to be proved.
The incidence of abnormal secretin-pancreozymin tests in the normal group was 7 % and the test was within normal limits in 12% of the patients with chronic pancreatic disease. While the secretinpancreozymin test provides information essential for both the diagnosis and the management of the patients with chronic pancreatitis and cancer of the pancreas (Howat, 1968a (Howat, , 1968b , it can prove uncomfortable for the patient and requires the presence of a technically skilled physician throughout the test. In this group the secretin-pancreozymin test was incomplete or was abandoned in 14 patients.
Conclusions
Excellent acceptance by patients and ease of technique combine to ensure the continued use of 75Se Selenomethionine scanning to screen patients for pancreatic disease in spite of its cost. In patients suspected of chronic pancreatitis and cancer of the pancreas a normal scan virtually eliminates the presence of pancreatic disease and no further investigations need be undertaken. When an abnormal scan is obtained, however, it is necessary to proceed to a specific test ofpancreatic function to discriminate between a normal pancreas which has not taken up the isotope and a pathological gland, and to establish a definitive diagnosis. We use the secretin-pancreozymin test for this purpose.
In a group of patients with chronic pancreatitis and cancer of the pancreas there is a close interrelation between abnormal scans and diminished exocrine secretion, especially bicarbonate output following a submaximal dose of secretin. However, 30 % of patients with a normal pancreas have abnormal scans. In this 30 % pancreatic function assessed by the secretin-pancreozymin test is normal.
Until more is known of the factors and constraints which regulate the uptake and distribution of 75Se Selenomethionine in abdominal and systemic disorders when the pancreas is normal, an abnormal scan cannot be equated with pancreatic malfunction.
